



SUBSECRETARÍA DE SALUD PÚBLICA
DIVISIÓN DE PLANIFICACIÓN SANITARIA
DEPARTAMENTO EVALUACIÓN DE TECNOLOGÍAS SANITARIAS Y SALUD BASADA EN EVIDENCIA

INFORME DE BÚSQUEDA Y SÍNTESIS DE COSTO-EFECTIVIDAD Guía de Práctica Clínica Cáncer Cérvico Uterino 2019

PREGUNTA: ¿EN MUJERES CON CÁNCER CERVICOUTERINO CON ENFERMEDAD RECURRENTE, PERSISTENTE O METASTÁSICA ¿SE DEBE “AÑADIR BEVACIZUMAB A QUIMIOTERAPIA” EN COMPARACIÓN A “NO AÑADIR”?

BÚSQUEDA DE EVALUACIONES ECONÓMICAS

La búsqueda consideró estudios de costo-efectividad y revisiones sistemáticas de evaluaciones de costo-efectividad de añadir bevacizumab a quimioterapia versus quimioterapia en personas con cáncer cervicouterino con enfermedad recurrente persistente o metastásica. Se identificaron términos MESH y términos de texto libre asociados a la población. La búsqueda consideró estudios publicados en inglés y español, en las siguientes bases de datos: MEDLINE, EMBASE, COCHRANE, GOOGLE, BRISA y en el National Institute for Health and Care Excellence (NICE).

Ver detalle en Anexo 1 “*Términos de Búsqueda y Resultados de la búsqueda*”.

SÍNTESIS DE EVIDENCIA SEGÚN PREGUNTA

Una vez ejecutada la búsqueda, se evaluaron los títulos y resúmenes de los estudios encontrados y se seleccionaron las evaluaciones económicas que utilizaran como método la costo-utilidad y costo-efectividad. Luego se realizó la extracción de datos de los estudios y se evaluó la calidad mediante la herramienta CHEERS (Consolidated Health Economic Evaluation Reporting Standards)

La búsqueda arrojó 133 artículos, luego se eliminaron los duplicados, éstos fueron evaluados por título y abstract, obteniéndose 3 artículos (1–3) para lectura a texto completo. A pesar de que estos artículos indican realizar un análisis de costo efectividad sobre la pregunta de investigación, ninguno de los tres reúne la calidad metodológica necesaria para informar al respecto.

Referencias

1. Phippen NT, Leath CA 3rd, Havrilesky LJ, Barnett JC. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? *Gynecol Oncol.* 2015 Jan;136(1):43–7.
2. N. K, A.C. W, K.M. S, K.J. M. Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable? *Clin Outcomes Res.* 2016;8:287–91.
3. L.E. M, J. B, B.J. M, L. RK, E.N. R, G.K. F, et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. *Gynecol Oncol.* 2015;137(3):490–6.

ANEXO 1: ESTRATEGIA DE BÚSQUEDA Y RESULTADOS DE LA BÚSQUEDA

| | Términos libres | DECS | MeSH |
|---|---|--|--|
| P | cáncer cervicouterino con enfermedad recurrente persistente o metastásica cervical cancer metastatic disease metastatic cervical cáncer recurrent disease | Uterine Cervical Neoplasms <ul style="list-style-type: none"> • Cancer of Cervix • Cancer of the Cervix • Cancer of the Uterine Cervix • Cancer, Cervix • Cancer, Uterine Cervical • Cancers, Cervix • Cancers, Uterine Cervical • Cervical Cancer • Cervical Cancer, Uterine • Cervical Cancers, Uterine • Cervical Neoplasm • Cervical Neoplasm, Uterine • Cervical Neoplasms • Cervical Neoplasms, Uterine • Cervix Cancer • Cervix Neoplasm • Cervix Neoplasms • Neoplasm, Cervical • Neoplasm, Cervix • Neoplasm, Uterine Cervical • Neoplasms, Cervical • Neoplasms, Cervix • Neoplasms, Uterine Cervical • Uterine Cervical Cancer • Uterine Cervical Cancers • Uterine Cervical Neoplasm Neoplasm Metastasis <ul style="list-style-type: none"> • Metastases • Metastases, Neoplasm • Metastasis • Metastasis, Neoplasm • Neoplasm Metastases | Uterine Cervical Neoplasms <ul style="list-style-type: none"> • Cervical Neoplasm, Uterine • Cervical Neoplasms, Uterine • Neoplasm, Uterine Cervical • Neoplasms, Uterine Cervical • Uterine Cervical Neoplasm • Neoplasms, Cervical • Cervical Neoplasms • Cervical Neoplasm • Neoplasm, Cervical • Neoplasms, Cervix • Cervix Neoplasms • Cervix Neoplasm • Neoplasm, Cervix • Cancer of the Uterine Cervix • Cancer of the Cervix • Cervical Cancer • Uterine Cervical Cancer • Cancer, Uterine Cervical • Cancers, Uterine Cervical • Cervical Cancer, Uterine • Cervical Cancers, Uterine • Uterine Cervical Cancers • Cancer of Cervix • Cervix Cancer • Cancer, Cervix • Cancers, Cervix Neoplasm Metastasis <ul style="list-style-type: none"> • Metastases, Neoplasm • Neoplasm Metastases • Metastasis • Metastases • Metastasis, Neoplasm |
| I | Bevacizumab Avastin | Bevacizumab <ul style="list-style-type: none"> • Avastin • Bevacizumab awwb • Bevacizumab-awwb • Mvasi | Bevacizumab <ul style="list-style-type: none"> • Mvasi • Bevacizumab-awwb • Bevacizumab awwb • Avastin |

| | | | |
|---|---|--|--|
| C | <p>Quimioterapia Chemotherapy Paclitaxel Cisplatino topotecán</p> | <p>Antineoplastic Combined Chemotherapy Protocols</p> <ul style="list-style-type: none"> • Agent, Combined Antineoplastic • Agents, Combined Antineoplastic • Anticancer Drug Combination • Anticancer Drug Combinations • Antineoplastic Agent, Combined • Antineoplastic Agents, Combined • Antineoplastic Chemotherapy Protocol • Antineoplastic Chemotherapy Protocols • Antineoplastic Combined Chemotherapy Regimens • Antineoplastic Drug Combination • Antineoplastic Drug Combinations • Cancer Chemotherapy Protocol • Cancer Chemotherapy Protocols • Chemotherapy Protocol, Antineoplastic • Chemotherapy Protocol, Cancer • Chemotherapy Protocols, Antineoplastic • Chemotherapy Protocols, Cancer • Combinations, Antineoplastic Drug • Combined Antineoplastic Agent • Combined Antineoplastic Agents • Drug Combination, Anticancer • Drug Combination, Antineoplastic | <p>Antineoplastic Combined Chemotherapy Protocols</p> <ul style="list-style-type: none"> • Combined Antineoplastic Agents • Antineoplastic Agents, Combined • Agent, Combined Antineoplastic • Agents, Combined Antineoplastic • Antineoplastic Agent, Combined • Combined Antineoplastic Agent • Antineoplastic Combined Chemotherapy Regimens • Drug Combinations, Antineoplastic • Anticancer Drug Combinations • Anticancer Drug Combination • Drug Combination, Anticancer • Drug Combinations, Anticancer • Antineoplastic Drug Combinations • Antineoplastic Drug Combination • Combinations, Antineoplastic Drug • Drug Combination, Antineoplastic • Antineoplastic Chemotherapy Protocols • Antineoplastic Chemotherapy Protocol • Chemotherapy Protocol, Antineoplastic • Protocol, Antineoplastic Chemotherapy • Protocols, Antineoplastic Chemotherapy • Cancer Chemotherapy Protocols |
|---|---|--|--|

| | | | |
|---|---|---|---|
| | | <ul style="list-style-type: none"> • Drug Combinations, Anticancer • Drug Combinations, Antineoplastic • Protocol, Antineoplastic Chemotherapy • Protocol, Cancer Chemotherapy • Protocols, Antineoplastic Chemotherapy • Protocols, Cancer Chemotherapy | <ul style="list-style-type: none"> • Cancer Chemotherapy Protocol • Chemotherapy Protocol, Cancer • Chemotherapy Protocols, Cancer • Protocol, Cancer Chemotherapy • Protocols, Cancer Chemotherapy • Chemotherapy Protocols, Antineoplastic |
| O | Cost effectiveness Cost utility Health technology assessment | Cost-Benefit Analysis <ul style="list-style-type: none"> • Analyses, Cost Benefit • Analyses, Cost-Benefit • Analyses, Cost-Utility • Analyses, Marginal • Analysis, Cost Benefit • Analysis, Cost-Benefit • Analysis, Cost-Effectiveness • Analysis, Cost-Utility • Analysis, Marginal • Benefits and Costs • Cost Benefit • Cost Benefit Analyses • Cost Benefit Analysis • Cost Benefit Data • Cost Effectiveness • Cost Effectiveness Analysis • Cost Utility Analysis • Cost-Benefit Analyses • Cost-Benefit Data • Cost-Effectiveness Analysis • Cost-Utility Analyses • Cost-Utility Analysis • Costs and Benefits • Data, Cost-Benefit • Economic Evaluation • Economic Evaluations • Effectiveness, Cost • Evaluation, Economic • Evaluations, Economic • Marginal Analyses | Cost-Benefit Analysis <ul style="list-style-type: none"> • Analyses, Cost-Benefit • Analysis, Cost-Benefit • Cost-Benefit Analyses • Cost Benefit Analysis • Analyses, Cost Benefit • Analysis, Cost Benefit • Cost Benefit Analyses • Cost Effectiveness • Effectiveness, Cost • Cost-Benefit Data • Cost Benefit Data • Data, Cost-Benefit • Cost-Utility Analysis • Analyses, Cost-Utility • Analysis, Cost-Utility • Cost Utility Analysis • Cost-Utility Analyses • Economic Evaluation • Economic Evaluations • Evaluation, Economic • Evaluations, Economic • Marginal Analysis • Analyses, Marginal • Analysis, Marginal • Marginal Analyses • Cost Benefit • Costs and Benefits • Benefits and Costs • Cost-Effectiveness Analysis • Analysis, Cost-Effectiveness • Cost Effectiveness Analysis Technology Assessment, Biomedical |

| | | | |
|--|--|--|--|
| | | <ul style="list-style-type: none"> • Marginal Analysis <p>Technology Assessment, Biomedical</p> <ul style="list-style-type: none"> • Assessment, Biomedical Technology • Assessment, Health Technology • Assessment, Technology • Assessments, Biomedical Technology • Assessments, Health Technology • Assessments, Technology • Biomedical Technology Assessment • Biomedical Technology Assessments • Health Technology Assessment • Health Technology Assessments • Technology Assessment • Technology Assessment, Health • Technology Assessments • Technology Assessments, Biomedical Technology Assessments, Health | <ul style="list-style-type: none"> • Biomedical Technology Assessment • Technology Assessment, Health • Assessment, Health Technology • Assessments, Health Technology • Health Technology Assessment • Health Technology Assessments • Technology Assessments, Health • Assessment, Biomedical Technology • Assessments, Biomedical Technology • Biomedical Technology Assessments • Technology Assessments, Biomedical • Technology Assessment • Assessment, Technology • Assessments, Technology Technology Assessments |
|--|--|--|--|

| Base de datos | Fecha de búsqueda | Resultados | Resultados después de remover duplicados |
|-----------------|-------------------|------------|--|
| Medline-Pubmed | 20-11-2019 | 25 | 25 |
| EMBASE | 20-11-2019 | 108 | 108 |
| NICE | 22-1-2019 | 0 | 0 |
| BRISA (RedETSA) | 22-11-2019 | 0 | 0 |
| COCHRANE | 22-11-2019 | 2 | 2 |
| GOOGLE | 22-11-2019 | 2 | 2 |
| Total | | | 133 |

Estrategias de Búsqueda

PUBMED

| Número | Búsqueda | Resultados |
|--------|---|------------|
| 12 | Search uterine cervical neoplasms[MeSH Terms] | 72893 |
| 13 | Search Neoplasm Metastasis[MeSH Terms] | 197822 |
| 14 | Search Bevacizumab[MeSH Terms] | 11047 |
| 15 | Search antineoplastic combined chemotherapy protocols[MeSH Terms] | 135565 |
| 16 | Search Cost-Benefit Analysis[MeSH Terms] | 78606 |
| 17 | Search technology assessment, biomedical[MeSH Terms] | 10856 |
| 18 | Search (("cervical cancer"[Title/Abstract] OR "cervix cancer"[Title/Abstract]) OR "uterine cervical cancer"[Title/Abstract]) | 45875 |
| 19 | Search ((#12) OR #13) OR #18 | 279863 |
| 20 | Search (bevacizumab[Title/Abstract]) OR avastin[Title/Abstract] | 15512 |
| 21 | Search (#20) OR #14 | 17368 |
| 22 | Search (((chemotherapy[Title/Abstract]) OR paclitaxel[Title/Abstract]) OR cisplatin[Title/Abstract]) OR topotecan[Title/Abstract] | 393886 |
| 23 | Search (#15) OR #22 | 446032 |
| 24 | Search ((((((("cost-effectiveness analysis"[Title/Abstract]) OR "cost effectiveness analysis"[Title/Abstract]) OR "economic evaluation"[Title/Abstract]) OR "Health technology assessment"[Title/Abstract]) OR "cost utility"[Title/Abstract]) OR #16) OR #17 | 97092 |
| 25 | Search (((#19) AND #21) AND #23) AND #24 | 25 |

EMBASE

| Número | Búsqueda | Resultados |
|--------|---|------------|
| 1 | uterine cervix tumor/ | 15628 |
| 2 | uterine cervix cancer/ | 60853 |
| 3 | metastasis/ or uterine cervix cancer/ or metastatic cervical cancer.mp. | 329350 |
| 4 | bevacizumab/ | 55312 |
| 5 | chemotherapy/ | 144130 |
| 6 | paclitaxel/ | 102062 |
| 7 | cisplatin/ | 177313 |
| 8 | topotecan/ | 11404 |
| 9 | "cost effectiveness analysis"/ or "cost minimization analysis"/ | 148077 |
| 10 | biomedical technology assessment/ | 13843 |
| 11 | "cost benefit analysis"/ | 82699 |
| 12 | economic evaluation/ | 15107 |
| 13 | "cervical cancer".ab. or "cervical cancer".ti. or "cervix cancer".ab. or "cervix cancer".ti. or "uterine cervical cancer".ti. or "uterine cervical cancer".ab. or "uterine cervical cancer".ti. | 61024 |
| 14 | Bevacizumab.ab. or Bevacizumab.ti. or Avastin.ab. or Avastin.ti. | 28315 |
| 15 | Chemotherapy.ab. or Chemotherapy.ti. or Paclitaxel.ab. or Paclitaxel.ti. or Cisplatin.ti. or Cisplatin.ab. or topotecan.ti. or topotecan.ab. | 607667 |

| | | |
|----|--|--------|
| 16 | "cost-effectiveness analysis".ab. or "cost-effectiveness analysis".ti. or "cost effectiveness analysis".ab. or "cost effectiveness analysis".ti. or "economic evaluation".ti. or "economic evaluation".ab. or "Health technology assessment".ti. or "Health technology assessment".ab. or "cost utility".ab. or "cost utility".ti. | 34204 |
| 17 | 1 or 3 or 13 | 358942 |
| 18 | 4 or 14 | 56708 |
| 19 | 5 or 6 or 7 or 8 or 15 | 709201 |
| 20 | 9 or 10 or 11 or 12 or 16 | 247387 |
| 21 | 17 and 18 and 19 and 20 | 108 |
| 22 | 17 and 18 and 20 | 185 |

NICE

Búsqueda: Bevacizumab

Sin resultados

BRISA

Búsqueda: Bevacizumab

Sin resultados

COCHRANE

| Número | Búsqueda | Resultados |
|--------|---|------------|
| 1 | ("cervical cancer"):ti,ab,kw OR ("uterine cancer"):ti,ab,kw OR ("metastases"):ti,ab,kw | 13230 |
| 2 | MeSH descriptor: [Uterine Cervical Neoplasms] explode all trees | 1927 |
| 3 | MeSH descriptor: [Neoplasm Metastasis] explode all trees | 4835 |
| 4 | #1 or #2 or #3 | 17845 |
| 5 | ("bevacizumab"):ti,ab,kw OR ("Avastin"):ti,ab,kw | 5747 |
| 6 | MeSH descriptor: [Bevacizumab] explode all trees | 1583 |
| 7 | #5 or #6 | 5747 |
| 8 | ("chemotherapeutical"):ti,ab,kw OR ("chemotherapeutic"):ti,ab,kw OR ("paclitaxel"):ti,ab,kw OR ("cisplatin"):ti,ab,kw OR ("topotecan"):ti,ab,kw | 22802 |
| 9 | MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees | 13173 |
| 10 | #9 or #8 | 31605 |
| 11 | ("cost effectiveness analyses"):ti,ab,kw OR ("cost effectiveness analysis"):ti,ab,kw OR ("health technology assessment"):ti,ab,kw | 11319 |
| 12 | MeSH descriptor: [Cost-Benefit Analysis] explode all trees | 6621 |
| 13 | MeSH descriptor: [Technology Assessment, Biomedical] explode all trees | 139 |
| 14 | #11 or #12 or #13 | 16024 |

| | | |
|----|---------------------------|---|
| 15 | #4 and #7 and #10 and #14 | 2 |
|----|---------------------------|---|

GOOGLE

Búsqueda: Bevacizumab "cervical cancer" cost-effectiveness

Resultados: 2